العربية
中国
Français
Deutsch
Ελληνική
हिन्दी
Italiano
日本語
Português
Русский
EspañolFDA APPROVES XYZAL®(levocetirizine dihydrochloride) TA
Title:
FDA APPROVES XYZAL®(levocetirizine dihydrochloride) TA
Description:
FDA APPROVES XYZAL®(levocetirizine dihydrochloride) TABLETS FOR THE RELIEF OF SEASONAL AND YEAR ROUND ALLERGIES, AND CHRONIC HIVES The U.S. Food and Drug Administration (FDA) has just approved Xyzal®, a new once-daily prescription antihistamine that delivers a rapid and long-lasting effect for the relief of symptoms associated with seasonal and year round allergies and chronic hives in adults and children six years of age and older. Estimates from the American College of Allergy, Asthma and Immunology suggest that allergies affect as many as 40 to 50 million people in the United States. As modern living has become more complex, so have allergies with the disease and subsequent allergy seasons becoming longer and more severe. Among others, outdoor pollution, indoor air quality problems, and exposure to airborne and food allergens are all playing a role in the surge in allergies. Xyzal® once-daily tablets are expected to be available during the 2007 fall allergy season. For more information as well as full prescribing information, visit http://www.ucb-group.com/products/allergy_respiratory_pc/xyzal/ or http://products.sanofi-aventis.us/xyzal/xyzal.pdf.
Author:
MultiVuOnline
Tags:
FDA, Xyzal, allergies, once-daily, prescription, antihistamine, Multivu, 28448,
FDA APPROVES XYZAL®(levocetirizine dihydrochloride) TA
Description:
FDA APPROVES XYZAL®(levocetirizine dihydrochloride) TABLETS FOR THE RELIEF OF SEASONAL AND YEAR ROUND ALLERGIES, AND CHRONIC HIVES The U.S. Food and Drug Administration (FDA) has just approved Xyzal®, a new once-daily prescription antihistamine that delivers a rapid and long-lasting effect for the relief of symptoms associated with seasonal and year round allergies and chronic hives in adults and children six years of age and older. Estimates from the American College of Allergy, Asthma and Immunology suggest that allergies affect as many as 40 to 50 million people in the United States. As modern living has become more complex, so have allergies with the disease and subsequent allergy seasons becoming longer and more severe. Among others, outdoor pollution, indoor air quality problems, and exposure to airborne and food allergens are all playing a role in the surge in allergies. Xyzal® once-daily tablets are expected to be available during the 2007 fall allergy season. For more information as well as full prescribing information, visit http://www.ucb-group.com/products/allergy_respiratory_pc/xyzal/ or http://products.sanofi-aventis.us/xyzal/xyzal.pdf.
Author:
MultiVuOnline
Tags:
FDA, Xyzal, allergies, once-daily, prescription, antihistamine, Multivu, 28448,
Popular searches: Cuba, Scuba Diving, Skydiving, Dubai, Niagara Falls, Rainforest, Surfing, Snowboarding, Sandboarding, Pyramids, Everest, Stonehenge, Bear Grylls
Related Videos:
 | FDA Approves First Drug to Help Patients with Parkinson's Di August 2006 (Medialink) -- Statistics: According to the National Parkinson Foundation (NPF), dementia is one of the complications most feared by Parkinson's disease patients and caregivers. Of the 1.5 million Americans living with the disease, an estimated 40% develop dementia. Story: The US Food and Drug Administration (FDA) has approved Exelon (rivastigmine tartrate) for the treatment of mild to moderate Parkinson's disease dementia, making it the first approved medication available for ... |
 | Hives - Delayed Pressure Urticaria - Part 3 This video concludes a 2 week trial of accupuncture. My experience with this particular accupuncturist did not yield good results...unfortunately. The next video will show footage of an "outbreak" that I am currently experiencing and will include a summary of a new doctor that I saw today (08/13/09). |
 | FDA Approves First Inhaled Insulin FDA recently approved Exubera, the first inhaled insulin product. It's a powdered form of recombinant human insulin that is self-administered using a specially designed inhaler. Exubera, manufactured by Pfizer, is intended to treat types 1 and 2 diabetes in patients over the age of 18. For patients with type 1 diabetes, Exubera can replace the short-acting insulin that is generally taken with meals, because with the inhaled form of insulin, patients can achieve peak levels of insulin quicker ... |
 | Allergy 3D Medical Animation This is a video on allergic mechanism in our body.this animation video shows how allergens come in contact and how does the body react to such allergens and what is the effect of anti histamine drugs over these allergens. rufusrajadurai.wetpaint.com |
 | FDA Fascists! A revealing look at the FDA. |
 | AAAAI: New Antihistamine Nasal Spray Works and Tastes Better www.medpagetoday.com Dale Mohar, MD, of Kerrville Allergy & Asthma Associates in Kerrville, Texas PHILADELPHIA -- Olopatadine in nasal spray form may provide an option to azelastine (Astelin) for seasonal allergic rhinitis, a researcher said here. |
 | Er!k eats 8 Airborne what the title says. |
 | Hives or Urticaria - Kid's Health Videos - DrTummy.com Michael Davis, MD, pediatrician, discusses hives or urticaria rashes in children. |
 | Vioxx and FDA Drug Injuries Discussion of Vioxx and FDA Drugs as defective products with attorney Brenda Fulmer, pharmaceutical injury litigation expert and partner in the law firm Alley, Clarke, Griewe, and Fulmer in Tampa, FL. Produced by injuryboard.com |
 | Cetirizine Zyrtec for more information, visit www.medicinecoach.com |
Popular searches: Cuba, Scuba Diving, Skydiving, Dubai, Niagara Falls, Rainforest, Surfing, Snowboarding, Sandboarding, Pyramids, Everest, Stonehenge, Bear Grylls
